

# Effect of Local Nasal Immunotherapy on Nasal Blockage in Pollen-Induced Allergic Rhinitis of Guinea Pigs

Takeshi Nabe<sup>1</sup>, Kayoko Kubota<sup>1</sup>, Nobuaki Mizutani<sup>1</sup>, Masanori Fujii<sup>1</sup>, Tetsuya Terada<sup>2</sup>, Hiroshi Takenaka<sup>2</sup> and Shigekatsu Kohno<sup>1</sup>

## ABSTRACT

**Background:** As a non-injection route for immunotherapy, local nasal immunotherapy has been examined in allergic rhinitis patients. However, it is unclear how the immunotherapy affects sneezing, biphasic nasal blockage and nasal hyperresponsiveness. Thus, we evaluated the therapeutic effects of nasal immunotherapy on the symptoms of guinea pig allergic rhinitis. Additionally, we also evaluated whether the immunotherapy relieved pollen-induced allergic conjunctivitis.

**Methods:** Sensitized animals were repeatedly challenged by pollen inhalation once every week. After the 7th challenge, the pollen extract was intranasally administered 6 times a week until the 30th challenge. Sneezing frequency was counted after each of the challenges. As an indicator of nasal blockage, changes in specific airway resistance were measured. Nasal hyperresponsiveness was assessed by measuring leukotriene D<sub>4</sub>-induced nasal blockage. Additionally, during the immunotherapy, we applied pollen onto the ocular surface to induce the allergic conjunctivitis symptoms.

**Results:** At the 11th–30th challenges, the nasal immunotherapy showed inhibition or a tendency to inhibit the biphasic nasal blockage although the inhibitions were variable at respective challenges. The development of nasal hyperresponsiveness was markedly suppressed by the immunotherapy. Nevertheless, neither sneezing nor antigen-specific IgE antibody production was substantially influenced by the immunotherapy. On the other hand, the nasal immunotherapy did not affect the induction of allergic conjunctivitis symptoms.

**Conclusions:** Local nasal immunotherapy may be clinically useful for allergic nasal blockage associated with nasal hyperresponsiveness. The mechanisms responsible for this effectiveness might not be related to IgE production. Additionally, the effectiveness for nasal tissue was dissociated from that seen for the ocular tissue.

## KEY WORDS

allergic rhinitis, animal model, local nasal immunotherapy, nasal blockage, pollenosis

## INTRODUCTION

In order to relieve the symptoms of pollenosis, specific immunotherapies have been developed that use subcutaneous administration of specific pollen antigens.<sup>1</sup> While subcutaneous immunotherapy has become an established therapeutic modality, it is also well known that subcutaneous injections of antigen can potentially result in the occurrence of life-threatening anaphylactic reactions.<sup>2</sup> Thus, to avoid such occurrences but still be able to provide specific immunotherapy, oral immunotherapy has been inves-

tigated and clinically tested in patients with allergic rhinitis.<sup>3</sup> However, generally higher doses of the allergen are needed when administered orally, which in some cases can induce a cytotoxic effect on the digestive tract.<sup>3</sup>

Another alternative non-injection route for immunotherapy is the use of local nasal immunotherapy. This administration method has been examined in patients with allergic rhinitis.<sup>4-8</sup> Local immunotherapy has an advantage in that only a small amount of the allergen is required as compared to that needed for the oral immunotherapeutic methods.<sup>3</sup> In most of the


<sup>1</sup>Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto and <sup>2</sup>Department of Otorhinolaryngology, Osaka Medical College, Osaka, Japan.  
Correspondence: Takeshi Nabe, Ph.D., Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical Uni-

versity, 5 Nakauchi, Misasagi, Yamashina, Kyoto 607-8414, Japan.

Email: nabe@mb.kyoto-phu.ac.jp

Received 2 June 2008. Accepted for publication 27 June 2008.

©2008 Japanese Society of Allergology



**Fig. 1** Schedule for sensitization and challenge with Japanese cedar pollen, and intranasal instillations of the pollen extract for the intranasal immunotherapy in guinea pigs. S: Sensitization with the pollen extract + Al(OH)<sub>3</sub> twice a day.

clinical examinations that have investigated local nasal immunotherapy, the therapy has been shown to be effective in the induction of allergic nasal signs.<sup>4-8</sup> However, due to the limitations of these previous clinical studies, it is not clear as to how the immunotherapy is able to affect the various nasal allergic symptoms, such as sneezing, biphasic nasal blockage and nasal hyperresponsiveness to non-specific stimuli. Thus, there is a need to examine the effects on local nasal mucosa using an experimental animal model of allergic rhinitis that has symptoms similar to those seen in clinical settings, and generate results that will help to elucidate the mechanisms underlying the therapeutic effect.

We have established a Japanese cedar pollen-induced allergic rhinitis guinea pig model.<sup>9-12</sup> In this model, after a pollen inhalation challenge, there is immediate sneezing and biphasically induced nasal blockage.<sup>10</sup> One of the characteristic features of experimental allergic rhinitis is that there is a markedly increased nasal responsiveness to intranasally instilled histamine or leukotriene (LT) D<sub>4</sub>.<sup>11,12</sup> Therefore, in the present study we tried to evaluate the effectiveness of local nasal immunotherapy in our experimental model. We also assessed whether nasal immunotherapy affected allergic conjunctivitis induced by dropping a pollen suspension into the eyes of test subjects.

## METHODS

### ANIMALS

Male, 3-week-old Hartley guinea pigs were purchased from Japan SLC (Hamamatsu, Japan). The animals were housed in an air-conditioned room at a temperature of 23 ± 1°C and 60 ± 10% humidity with the lights on from 8:00 a.m. to 8:00 p.m. Animals were fed a standard laboratory diet and given water *ad libitum*. The first sensitization was started 2 weeks after the arrival of the guinea pigs.

This animal study was approved by the Experimen-

tal Animal Research Committee at the Kyoto Pharmaceutical University.

### ANTIGEN AND ADJUVANT

Japanese cedar (*Cryptomeria japonica*) pollen was harvested in Gifu and Shiga prefectures (Japan) in 1998. Al (OH)<sub>3</sub> gels were prepared with 0.25 N NaOH and 0.25 N Al<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub>, as has been previously described.<sup>13</sup>

The cedar pollen extract used for the sensitization was prepared as follows. The pollen was suspended in PBS at 100 mg/ml followed by vigorous stirring at 4°C for 48 hours. The suspension was then centrifuged and the supernatant collected. Protein concentration in the supernatant was measured using the method of Bensadoun and Weinstein.<sup>14</sup> The extract was combined with an Al(OH)<sub>3</sub> suspension to achieve a concentration of 100 µg protein/100 mg Al (OH)<sub>3</sub>/ml.

The pollen extract used for the local nasal immunotherapy was prepared by centrifuging (4°C, 31,000 x g, 30 minutes) the pollen suspension (100 mg/ml) after stirring for 48 hours. The supernatant collected was then used for intranasal administration for the immunotherapy.

### SENSITIZATION AND CHALLENGE (Fig. 1)

Using a previously described method,<sup>10</sup> guinea pigs were sensitized by bilateral intranasal instillation of the cedar pollen extract that was adsorbed onto the Al(OH)<sub>3</sub> gel at a concentration of 0.3 µg protein/0.3 mg Al(OH)<sub>3</sub>/3 µl/each nostril twice a day for 7 days. To prevent rapid elimination of the antigen by ciliary movement, the upper airway mucosal surface was anesthetized through the use of a 2-min inhalation of a mist of 4% lidocaine hydrochloride solution (MP Biomedicals, Solon, OH, USA) that was generated by an ultrasonic nebulizer (NE-U12, Omron, Osaka, Japan) prior to each sensitization session. The sensitized animals were then intranasally challenged once

every week by inhalation of cedar pollen using a handmade inhalation apparatus,<sup>9</sup> which was designed to allow for the quantitative inhalation of pollen. The apparatus was loaded with 3 mg of pollen and then positioned in one nostril of the conscious guinea pig for 1 minute so that during spontaneous breathing, the animal inhaled approximately 1.8 mg/nostril of the pollen. During the inhalation, the other nostril was plugged with a finger, with the procedure then repeated a second time for the other nostril. As a negative control, a sensitized non-challenged group was prepared for the experiments that assessed nasal responsiveness to LTD<sub>4</sub>.

### **INTRANASAL ADMINISTRATION OF THE CEDAR POLLEN EXTRACT FOR IMMUNOTHERAPY (Fig. 1)**

Starting on the 1st day after the 7th challenge and until 1 day before the 30th challenge, 6 times per week, 0.003 and 0.3 mg of pollen-derived extract/animal was intranasally administered at a volume of 20  $\mu$ l/animal. Control animals were treated with PBS instead of the extract. There was no intranasal administration for immunotherapy carried out on the days of the pollen inhalation challenge.

In order to check whether the instillations of the pollen extract at the immunotherapy induced nasal symptoms, time-course changes in sneezing frequency and the specific airway resistance (sRaw) were measured after an instillation of the extract on days 15 and 86 after the start of immunotherapy.

### **COUNTING OF SNEEZING FREQUENCY**

Sneezing frequency was counted during the first hour after the pollen inhalation challenge.

### **MEASUREMENT OF SPECIFIC AIRWAY RESISTANCE (sRaw)**

sRaw was used as an indicator of the nasal blockage. A two-chambered, double-flow plethysmograph system along with a data analyzer Pulmos-I (MIPS, Osaka, Japan) were used to measure the sRaw, in accordance with the method of Pennock *et al.*<sup>15</sup>

### **MEASUREMENT OF NASAL RESPONSIVENESS TO LTD<sub>4</sub>**

Nasal responsiveness to intranasally instilled LTD<sub>4</sub> was measured 2 days after the 16th and 30th pollen inhalation challenges, as has been previously described.<sup>12</sup> At 20-minute intervals, increasing doses (10  $\mu$ l/each nostril) of the LTD<sub>4</sub> solution (0.01 and 0.1  $\mu$ M) were bilaterally applied. sRaw was measured 10 minutes after each of the respective agonist doses.

### **MEASUREMENT OF Cry j 1- AND Cry j 2-SPECIFIC IgE ANTIBODIES IN SERA**

Cry j 1- and Cry j 2-specific IgE antibodies were determined by an enzyme-linked immunosorbent assay

(ELISA) kit<sup>16</sup> (Guinea pig IgE ELISA MARUPI, Dainippon Pharmaceutical Co., Osaka, Japan) using blood samples collected 1 day before the 15th and 29th inhalation challenges. As this kit is designed for the measurement of total IgE in the guinea pig, we modified the method provided by the manufacturer in order that we could measure Cry j 1- and Cry j 2-specific IgEs, as has been previously described.<sup>17</sup>

Values for Cry j 1- and Cry j 2-specific IgE levels in tested sera were expressed in arbitrary units relative to the value of a pooled standard serum from the sensitized challenged guinea pigs. The standard serum was prepared by an i.p. injection of the pollen extract adsorbed onto Al(OH)<sub>3</sub> once every week for a total of 9 times in naïve guinea pigs. The sera were collected 2 weeks after the last sensitization, followed by a subsequent pooling of all sera obtained. Cry j 1- and Cry j 2-specific IgE titers of the pooled serum were regarded as 1000 u/ml.

### **INDUCTION OF ALLERGIC CONJUNCTIVITIS**


On the days prior to the 26th through the 28th inhalation challenges, animals were challenged by dropping a pollen suspension (2 mg pollen/10  $\mu$ l/eye) in each eye, as has been previously reported.<sup>18,19</sup> The magnitude of conjunctival edema and redness was judged macroscopically and expressed as a conjunctivitis intensity score (CIS) according to an arbitrary 5-point graded scale, from 0 to 4 (0, no symptoms; 1, light; 2, mild; 3, moderate; 4, severe).<sup>20</sup>

Scratching frequencies at 0–0.5 hours after the respective 1st–3rd ophthalmic challenges were counted. The scratch response was defined as an uninterrupted cluster of rapid hindlimb movements that were precisely directed to the ocular surface.

Ophthalmic lavage fluid was collected before and 0.5 hours after the 3rd challenge, with the amount of albumin measured by an enzyme-linked immunosorbent assay in accordance with the method of Gawin *et al.*<sup>21</sup> In brief, 10  $\mu$ l of sterile physiologic saline was applied to the eye using a micropipette, followed by two or three forced blinks, with the fluid then subsequently collected. The lavage was repeated 5 times in each eye. Once lavage fluids were obtained from both eyes, the collected fluids were then combined. Following the centrifugation of the fluid, the supernatant was used for the measurement of albumin.

### **STATISTICAL ANALYSES**

Statistical analysis was performed by one-way analysis of variance. If a significant difference was detected, the individual group difference was determined by Bonferroni's multiple test. A probability value (*P*) < 0.05 was considered to be statistically significant.



**Fig. 2** (A) Time-course change in specific airway resistance (sRaw) after the 7th inhalation challenge with Japanese cedar pollen in sensitized guinea pigs. Based on the results at the 7th challenge, 22 animals were divided into 3 groups that consisted of control and nasal immunotherapy groups that were treated with either 0.003 or 0.3 mg pollen-derived extract. Each point represents the mean  $\pm$  S.E. of 22 animals. (B, C, D and E) Effect of nasal immunotherapy on early (EPR) and late phase response (LPR) of the biphasic nasal blockage induced by the 9th (B), 11th (C), 16th (D) and 30th (E) inhalation challenges. One day after the 7th challenge and continuing until the 30th challenge, 0.003 or 0.3 mg pollen-derived extract was intranasally administered 6 times a week. EPR and LPR are expressed as the area under the response curve (AUC) for the change in the specific airway resistance (sRaw) at 0–2 hours and 3–6 hours after the challenges, respectively. Each column represents the mean  $\pm$  S.E. of 7 or 8 animals. \* $p < 0.05$  vs. control.

## RESULTS

### EFFECT ON THE BIPHASIC NASAL BLOCKAGE

The 7th pollen inhalation challenge induced biphasic nasal blockage (Fig. 2A), as has been previously reported.<sup>10</sup> Starting on the 1st day after the 7th challenge, the pollen extract was intranasally administered 6 times a week. Figure 2B–E show the effect of the local intranasal immunotherapy on the biphasic nasal blockage for the 9th–30th inhalation challenges. Early (EPR) and late phase responses (LPR) are expressed as the area under the response curve (AUC) for the changes in sRaw at 0–2 hours and 3–6 hours after the challenge, respectively. The nasal immunotherapy significantly inhibited both the EPR and LPR at the 11th challenge (Fig. 2C). The tendency to inhibit the nasal blockage was observed at the 16th and


30th challenges, whereas the inhibitions were variable, and not statistically significant (Fig. 2D, E).

### EFFECTS ON SNEEZING

As previously reported,<sup>10</sup> induction of sneezing occurred within 1 hour after the respective pollen inhalation challenges, with sneezing frequencies of 10–20 times/hour. In contrast to the effects seen for the nasal blockage, the nasal immunotherapy did not substantially affect the frequency of sneezing that was induced at the 9th–30th inhalation challenges (Fig. 3A–D).

### EFFECT ON THE DEVELOPMENT OF NASAL HYPERRESPONSIVENESS TO LTD<sub>4</sub>

Consistent with our previous findings,<sup>12</sup> nasal responsiveness to LTD<sub>4</sub> in the control group was markedly



**Fig. 3** Effect of the nasal immunotherapy on the occurrence of sneezing induced by the 9th (A), 11th (B), 16th (C) and 30th (D) inhalation challenges with Japanese cedar pollen in sensitized guinea pigs. As described in Fig. 1, extract derived from 0.003 or 0.3 mg pollen was intranasally administered. During the first hour after each challenge, sneezing frequency was counted. Each column represents the mean  $\pm$  S.E. of 7 or 8 animals.

higher as compared with the sensitized non-challenged guinea pig 2 days after the 16th and 30th challenges (Fig. 4A, B). The development of nasal hyperresponsiveness after the challenges was almost completely suppressed by the local nasal immunotherapy (Fig. 4A, B).

#### LACK OF INDUCTION OF NASAL SYMPTOMS AFTER INTRANASAL INSTILLATION OF THE EXTRACT DURING IMMUNOTHERAPY

The effect of instillation of the extract during immunotherapy on induction of sneezing and nasal blockage was assessed on days 15 and 86 after the start of the immunotherapy. As shown in Table 1, 2, neither nasal blockage at 1 and 4 hours after the instillation nor sneezing within 1 hour was induced in 0.003 and 0.3 mg pollen-derived extract-treated groups.

#### INFLUENCE ON Cry j 1- AND Cry j 2-SPECIFIC IgE PRODUCTION

Large amounts of both Cry j 1- and Cry j 2-specific IgEs were detected in the sera at the 15th and 29th inhalation challenges. Local nasal immunotherapy had no effect on the production of IgE (Fig. 5A, B).


#### EFFECT ON POLLEN-INDUCED ALLERGIC CONJUNCTIVITIS

We also assessed whether local nasal immunotherapy suppressed pollen-induced allergic conjunctivitis. There was an apparent increase in the CIS even at the 1st ophthalmic challenge with the pollen, with the

increase peaking at 0.5 hours. The scratching frequency was also increased within 1 hour after the 1st challenge. Both responses tended to be intensified at the subsequent 2nd and 3rd challenges. However, the nasal immunotherapy did not affect the induction of the allergic conjunctivitis symptoms (Fig. 6A-F). The amount of albumin in the ophthalmic lavage fluid, which is an indicator of plasma extravasation, was increased after the 3rd pollen challenge in the eye. This increase in the albumin amount was not affected by the nasal immunotherapy (Fig. 6G).

#### DISCUSSION

In the present study, therapeutic effects of nasal immunotherapy on the induction of allergic rhinitis symptoms were evaluated in guinea pigs. Results indicated that biphasic nasal blockage, which consists of both EPR and LPR, was suppressed by nasal immunotherapy at the 11th–30th challenges, although the influences were variable at respective challenges and not apparent. Nasal responsiveness to intranasal application of LTD<sub>4</sub> was markedly increased in the control animals at the 16th and 30th challenges. Interestingly, the development of nasal hyperresponsiveness was completely inhibited by the immunotherapy. Nevertheless, neither sneezing nor Cry j 1- and Cry j 2-specific IgE production was influenced by the therapy. On the other hand, after an intranasal administration of 0.003 and 0.3 mg pollen-derived extract, there were no nasal symptoms in the sensitized guinea pigs, as shown by the sRaw and sneezing fre-



**Fig. 4** Effect of the nasal immunotherapy on the increase of nasal responsiveness to leukotriene (LT) D<sub>4</sub> after the 16th (**A**) and 30th (**B**) inhalation challenges with Japanese cedar pollen in sensitized guinea pigs. Extract derived from 0.003 or 0.3 mg pollen was intranasally administered as described in Fig. 1. The nasal responsiveness to intranasal instillation of 0.01 and 1 µM LTD<sub>4</sub> was assessed 2 days after the challenges. Each point represents the mean ± S.E. of 7 or 8 animals. \*  $p < 0.05$ , \*\*  $p < 0.01$  and \*\*\*  $p < 0.001$  vs. control, †  $p < 0.05$ , ††  $p < 0.01$  and †††  $p < 0.001$  vs. sensitized-non-challenged group.

**Table 1** Lack of induction of nasal blockage after intranasal instillation of the pollen extract for the immunotherapy

Day	Changes in sRaw at 1 hour [cmH <sub>2</sub> Oxml/(ml/s)]			Changes in sRaw at 4 hours [cmH <sub>2</sub> Oxml/(ml/s)]		
	Control	0.003 mg	0.3 mg	Control	0.003 mg	0.3 mg
15	0.19 ± 0.12	0.30 ± 0.14	0.24 ± 0.10	0.23 ± 0.15	0.14 ± 0.15	0.15 ± 0.11
86	0.05 ± 0.09	0.06 ± 0.14	-0.04 ± 0.15	0.03 ± 0.12	-0.02 ± 0.14	-0.01 ± 0.16

Extract derived from 0.003 or 0.3 mg pollen was intranasally administered as described in Fig. 1. Specific airway resistance (sRaw) was measured before, and 1 and 4 hours after the intranasal instillation of the extract on days 15 and 86 after the start of the immunotherapy. Each value represents the mean ± S.E. of 8 animals.

quency measurements. Thus, the effects of the nasal immunotherapy may not be due to a decreased anaphylactic reaction that had been influenced by repeated antigen-antibody reactions at the nasal mucosa.

The present results are essentially similar to our previous study that examined the therapeutic effect of oral immunotherapy in this experimental allergic rhinitis model.<sup>17</sup> In our oral immunotherapy study, 1 mg pollen-derived extract was orally administered until the 30th challenge and was found to be effective in biphasic nasal blockage and in the development of nasal hyperresponsiveness, although no effects were noted on IgE production or on the occurrence of sneezing.<sup>17</sup> The magnitudes of the inhibition in the

development of the nasal hyperresponsiveness by the nasal immunotherapy when using 0.003 and 0.3 mg pollen-induced extract in the present study were almost equipotent to that seen in our previous oral immunotherapy study that used a 1 mg pollen-derived extract.<sup>17</sup> Although we have not examined the dose-dependent effect of the oral immunotherapy, local nasal immunotherapy is effective at relatively low doses of antigen, similar to that which has been reported in clinical trials.<sup>3</sup>

In most local nasal immunotherapy clinical trials for allergic rhinitis, nasal immunotherapy effectively relieved the symptoms of allergic rhinitis, whereas allergen-specific IgE production was not inhibited.<sup>4-8</sup> Our present results are consistent with these clinical

findings.<sup>4-8</sup> We have also previously reported that the sneezing which was induced within 1 hour after challenge was almost completely suppressed by treatment with anti-histaminics.<sup>22</sup> This indicates that the histamine that is released from the mast cells immediately after the pollen inhalation plays a major role in the occurrence of sneezing. Nevertheless, local nasal immunotherapy inhibited neither the induction of sneezing nor the increase of Cry j 1- and Cry j 2-specific IgE levels. These findings are similar to the results from our previous experiment that assessed the effects of oral immunotherapy,<sup>17</sup> and indicate that nasal immunotherapy has no inhibitory effect on the IgE-mediated mast cell activation at the nasal mu-

cosa.


However, presently there are no clear mechanisms that can explain the effectiveness of the local nasal immunotherapy on the development of nasal hyperresponsiveness other than by inhibition of IgE production and mast cell activation. However, the effectiveness of the nasal immunotherapy was similar to the results we obtained for the oral immunotherapy in our previous study.<sup>17</sup> Thus, it can be speculated that even though the treatments for the intranasally and orally applied allergens were different in the nasal- and gut-associated lymphoid tissues, respectively, hyporesponsiveness to the allergen may be required for both of these immunotherapy cases. Because recognition of allergen by a specific IgE may not be affected by the immunotherapy described above, it can be speculated that antigen recognition by antigen-presenting cells may be decreased, thus leading to suppression of the nasal hyperresponsiveness. Further detailed analyses need to be conducted in order to elucidate these mechanisms.

On the other hand, the pollen-induced allergic conjunctivitis was not affected by the nasal immunotherapy even though there was sustained effectiveness in the nasal tissue. The dissociation of the effectiveness of the nasal immunotherapy between the nasal and conjunctivitis tissues has also been reported in a previous clinical examination.<sup>7</sup> It may well be that the nasal immunotherapy is effective only on the local or-


**Table 2** Lack of induction of sneezing after intranasal instillation of the pollen extract for the immunotherapy

Day	Sneezing frequency (times/hour)		
	Control	0.003 mg	0.3 mg
15	0.3 ± 0.2	0.4 ± 0.3	0.5 ± 0.3
86	0.8 ± 0.4	0.5 ± 0.3	0.8 ± 0.2

Extract derived from 0.003 or 0.3 mg pollen was intranasally administered as described in Fig. 1. Sneezing frequency was counted 0–1 hour after the intranasal instillation of the extract on days 15 and 86 after the start of the immunotherapy. Each value represents the mean ± S.E. of 8 animals.



**Fig. 5** Effect of the nasal immunotherapy on the production of Cry j 1- (**A**) and Cry j 2- (**B**) specific IgEs at the 15th and 29th inhalation challenges with Japanese cedar pollen in sensitized guinea pigs. Extract derived from 0.003 or 0.3 mg pollen was intranasally administered as described in Fig. 1. Sera were drawn 1 day before each challenge. Each point represents the mean ± S.E. of 7 or 8 animals.



**Fig. 6** Effect of the nasal immunotherapy on the Japanese pollen-induced allergic conjunctivitis in the sensitized guinea pigs. Extract derived from 0.003 or 0.3 mg pollen was intranasally administered as described in Fig. 1. During the nasal immunotherapy (1 day before the 26th, 27th and 28th challenges), animals were challenged by dropping a pollen suspension in each eye for a total of 3 times. (**A, B and C**) The magnitude of conjunctival edema and redness were macroscopically judged at 0–5 hours after the respective 1st–3rd ophthalmic challenges, and expressed as the conjunctivitis intensity score (CIS). (**D, E and F**) Scratching frequencies at 0–0.5 hours after the respective 1st–3rd challenges were counted. (**G**) Albumin amounts in the ophthalmic lavage fluid that was collected before and 0.5 hour after the 3rd challenge were measured by an enzyme-linked immunosorbent assay. Each point or column represents the mean  $\pm$  S.E. of 7 or 8 animals.

gans, which are controlled by the nasal-associated lymphoid tissue. However, in one of our previous studies, oral immunotherapy, which may affect the systemic immune system, was also found to be effective for nasal allergic symptoms even though it did not have any effect on the conjunctival allergies (unpublished data). Thus, the immunological induction mechanisms underlying the nasal blockage and hy-

perresponsiveness might be largely different from those in allergic conjunctivitis. We have previously reported that scratching incidence, increases in CIS, and albumin leakage are all immediate allergic responses that peak at around 30 minutes after a pollen challenge.<sup>18,19,23</sup> These findings suggest that these responses are part of an IgE-dependent allergy, much like the case of sneezing that is seen in the allergic



rhinitis model. These results also provide further support for the rationale that we can exclude the effects on IgE-mediated mast cell activation as being a part of the mechanism of this immunotherapy.

In conclusion, there was effective suppression of both the biphasic nasal blockage and the development of nasal hyperresponsiveness induced by the subsequent pollen inhalation challenges in sensitized guinea pigs undergoing intranasal administration of pollen extract 6 times a week, although there was no suppression of the sneezing. This inhibition was not related to serum antigen-specific IgE levels. The effectiveness of this local nasal immunotherapy might be due to a nasal hyposensitization mechanism to the specific allergen.

## ACKNOWLEDGEMENTS

This work was supported by the 21st COE Program from the Ministry of Education, Culture, Sports, Science and Technology-Japan. In addition, this study was supported in part by the "High-Tech Research Center" Project for Private Universities: matching fund subsidy from MEXT (Ministry of Education, Culture, Sports, Science and Technology), 2004–2008.

## REFERENCES

1. Valovirta E. Preventive capacity of subcutaneous immunotherapy. *Curr Opin Allergy Clin Immunol* 2002;**2**:553-6.
2. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. *J Allergy Clin Immunol* 1992;**90**:567-78.
3. Canonica GW, Passalacqua G. Noninjection routes of immunotherapy. *J Allergy Clin Immunol* 2003;**111**:437-48.
4. Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response. *J Allergy Clin Immunol* 1981;**68**:33-40.
5. Weish PW, Zimmermann EM, Yunginger JW, Kern EB, Gleich GJ. Preseasonal intranasal immunotherapy with nebulized short ragweed extract. *J Allergy Clin Immunol* 1981;**67**:237-42.
6. Schumacher MJ, Pain MC. Intranasal immunotherapy and polymerized grass pollen allergens. *Allergy* 1982;**37**:241-8.
7. Georgitis JW, Reisman RE, Clayton WF, Mueller UR, Wypych JI, Arbesman CE. Local intranasal immunotherapy for grass-allergic rhinitis. *J Allergy Clin Immunol* 1983;**71**:71-6.
8. Marcucci F, Sensi LG, Caffarelli C *et al.* Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to *Dermatophagoides*. *Allergy* 2002;**57**:23-8.
9. Nabe T, Shimizu K, Mizutani N *et al.* A new model of experimental allergic rhinitis using Japanese cedar pollen in guinea pigs. *Jpn J Pharmacol* 1997;**75**:243-51.
10. Nabe T, Mizutani N, Shimizu K, Takenaka H, Kohno S. Development of pollen-induced allergic rhinitis with early and late phase nasal blockage in guinea pigs. *Inflamm Res* 1998;**47**:369-74.
11. Mizutani N, Nabe T, Sasaki K, Takenaka H, Kohno S. Nasal hyperresponsiveness to histamine induced by repetitive exposures to cedar pollen in guinea-pigs. *Eur Respir J* 1999;**14**:1368-75.
12. Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H, Kohno S. Markedly increased nasal blockage by intranasal leukotriene D<sub>4</sub> in an experimental allergic rhinitis model: contribution of dilated mucosal blood vessels. *Jpn J Pharmacol* 2001;**86**:170-82.
13. Nabe T, Shinoda N, Yamashita K, Yamada M, Yamamura H, Kohno S. Comparative studies on nebulizers for antigen inhalation in experimental asthma. *Allergol Int* 1997;**46**:261-7.
14. Bensadoun A, Weinstein D. Assay of protein in the presence of interfering materials. *Anal Biochem* 1976;**70**:241-50.
15. Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH. A noninvasive technique for measurement of changes in specific airway resistance. *J Appl Physiol* 1979;**46**:399-406.
16. Nishimura M, Funaoka H, Hosoe H *et al.* Development and evaluation of a direct sandwich enzyme-linked immunosorbent assay for the quantification of guinea-pig immunoglobulin e. *J Pharmacol Sci* 2006;**101**:58-65.
17. Nabe T, Kubota K, Terada T, Takenaka H, Kohno S. Effect of oral immunotherapy on nasal blockage in experimental allergic rhinitis. *J Pharmacol Sci* 2005;**98**:380-7.
18. Yasuda M, Kato M, Nabe T, Nakata K, Kohno S. An experimental allergic conjunctivitis induced by topical and repetitive applications of Japanese cedar pollens in guinea pigs. *Inflamm Res* 1999;**48**:325-36.
19. Fukushima Y, Nabe T, Mizutani N, Nakata K, Kohno S. Multiple cedar pollen challenge diminishes involvement of histamine in allergic conjunctivitis of Guinea pigs. *Biol Pharm Bull* 2003;**26**:1696-700.
20. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketrolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. *Surv Ophthalmol* 1993;**38**(Suppl):141-8.
21. Gawin AZ, Emery BE, Baraniuk JN, Kaliner MA. Nasal glandular secretory response to cholinergic stimulation in humans and guinea pigs. *J Appl Physiol* 1991;**71**:2460-8.
22. Yamasaki M, Mizutani N, Sasaki K *et al.* Involvement of thromboxane A<sub>2</sub> and peptide leukotrienes in early and late phase nasal blockage in a guinea pig model of allergic rhinitis. *Inflamm Res* 2001;**50**:466-73.
23. Katayama G, Nabe T, Fujii M, Kohno S. Mast cell hyperplasia induced by multiple challenge with cedar pollen in sensitized guinea pigs. *Inflamm Res* 2005;**54**:370-4.